Immunitybio Net Income
| IBRX Stock | USD 5.95 0.67 10.12% |
As of the 13th of February 2026, Immunitybio retains the Risk Adjusted Performance of 0.2115, downside deviation of 4.7, and Market Risk Adjusted Performance of 3.57. Immunitybio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Immunitybio Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 81.2953 | Revenue | Earnings Share (0.41) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -372.3 M | -353.7 M | |
| Net Loss | -374.9 M | -356.2 M | |
| Net Loss | -372.3 M | -390.9 M | |
| Net Loss | (0.68) | (0.72) | |
| Net Income Per E B T | 1.15 | 1.10 |
Immunitybio | Net Income | Build AI portfolio with Immunitybio Stock |
The evolution of Net Income for Immunitybio provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Immunitybio compares to historical norms and industry peers.
Latest Immunitybio's Net Income Growth Pattern
Below is the plot of the Net Income of Immunitybio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Immunitybio financial statement analysis. It represents the amount of money remaining after all of Immunitybio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Immunitybio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (413.64 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Immunitybio Net Income Regression Statistics
| Arithmetic Mean | (196,370,401) | |
| Coefficient Of Variation | (94.92) | |
| Mean Deviation | 161,610,072 | |
| Median | (120,809,000) | |
| Standard Deviation | 186,385,730 | |
| Sample Variance | 34739.6T | |
| Range | 581.1M | |
| R-Value | (0.86) | |
| Mean Square Error | 9775.9T | |
| R-Squared | 0.74 | |
| Significance | 0.000011 | |
| Slope | (31,669,071) | |
| Total Sum of Squares | 555834.2T |
Immunitybio Net Income History
Other Fundumenentals of Immunitybio
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Immunitybio Net Income component correlations
Immunitybio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunitybio is extremely important. It helps to project a fair market value of Immunitybio Stock properly, considering its historical fundamentals such as Net Income. Since Immunitybio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunitybio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunitybio's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. Market participants price Immunitybio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immunitybio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Immunitybio requires distinguishing between market price and book value, where the latter reflects Immunitybio's accounting equity. The concept of intrinsic value - what Immunitybio's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Immunitybio's price substantially above or below its fundamental value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunitybio's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Immunitybio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immunitybio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immunitybio.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Immunitybio on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Immunitybio or generate 0.0% return on investment in Immunitybio over 90 days. Immunitybio is related to or competes with Arcus Biosciences, Denali Therapeutics, Cogent Biosciences, Galapagos, Beam Therapeutics, Recursion Pharmaceuticals, and Liquidia Technologies. ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement,... More
Immunitybio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immunitybio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immunitybio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.7 | |||
| Information Ratio | 0.2394 | |||
| Maximum Drawdown | 51.87 | |||
| Value At Risk | (7.11) | |||
| Potential Upside | 14.55 |
Immunitybio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunitybio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immunitybio's standard deviation. In reality, there are many statistical measures that can use Immunitybio historical prices to predict the future Immunitybio's volatility.| Risk Adjusted Performance | 0.2115 | |||
| Jensen Alpha | 1.97 | |||
| Total Risk Alpha | 1.3 | |||
| Sortino Ratio | 0.4131 | |||
| Treynor Ratio | 3.56 |
Immunitybio February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.2115 | |||
| Market Risk Adjusted Performance | 3.57 | |||
| Mean Deviation | 5.32 | |||
| Semi Deviation | 3.89 | |||
| Downside Deviation | 4.7 | |||
| Coefficient Of Variation | 401.02 | |||
| Standard Deviation | 8.1 | |||
| Variance | 65.68 | |||
| Information Ratio | 0.2394 | |||
| Jensen Alpha | 1.97 | |||
| Total Risk Alpha | 1.3 | |||
| Sortino Ratio | 0.4131 | |||
| Treynor Ratio | 3.56 | |||
| Maximum Drawdown | 51.87 | |||
| Value At Risk | (7.11) | |||
| Potential Upside | 14.55 | |||
| Downside Variance | 22.06 | |||
| Semi Variance | 15.1 | |||
| Expected Short fall | (7.13) | |||
| Skewness | 2.27 | |||
| Kurtosis | 8.23 |
Immunitybio Backtested Returns
Immunitybio is unstable given 3 months investment horizon. Immunitybio holds Efficiency (Sharpe) Ratio of 0.25, which attests that the entity had a 0.25 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 2.1% are justified by taking the suggested risk. Use Immunitybio Market Risk Adjusted Performance of 3.57, risk adjusted performance of 0.2115, and Downside Deviation of 4.7 to evaluate company specific risk that cannot be diversified away. Immunitybio holds a performance score of 19 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 0.57, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immunitybio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immunitybio is expected to be smaller as well. Use Immunitybio maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Immunitybio.
Auto-correlation | 0.22 |
Weak predictability
Immunitybio has weak predictability. Overlapping area represents the amount of predictability between Immunitybio time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immunitybio price movement. The serial correlation of 0.22 indicates that over 22.0% of current Immunitybio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.22 | |
| Spearman Rank Test | 0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 3.79 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Immunitybio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Immunitybio reported net income of (413.64 Million). This is 221.2% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 172.44% higher than that of the company.
Immunitybio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunitybio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics of similar companies.Immunitybio is currently under evaluation in net income category among its peers.
Immunitybio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunitybio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunitybio's managers, analysts, and investors.Environmental | Governance | Social |
Immunitybio Institutional Holders
Institutional Holdings refers to the ownership stake in Immunitybio that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Immunitybio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunitybio's value.| Shares | Citigroup Inc | 2025-06-30 | 2.5 M | Tang Capital Management Llc | 2025-06-30 | 2.3 M | Susquehanna International Group, Llp | 2025-06-30 | 1.9 M | Northern Trust Corp | 2025-06-30 | 1.8 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1.8 M | Royal Bank Of Canada | 2025-06-30 | 1.2 M | Ubs Group Ag | 2025-06-30 | 1.2 M | Jpmorgan Chase & Co | 2025-06-30 | 1.1 M | Bsc Private Wealth Management, Llc | 2025-06-30 | 846.4 K | Vanguard Group Inc | 2025-06-30 | 21.8 M | Blackrock Inc | 2025-06-30 | 17.8 M |
Immunitybio Fundamentals
| Return On Asset | -0.37 | ||||
| Operating Margin | (1.74) % | ||||
| Current Valuation | 6.71 B | ||||
| Shares Outstanding | 984.97 M | ||||
| Shares Owned By Insiders | 66.41 % | ||||
| Shares Owned By Institutions | 16.20 % | ||||
| Number Of Shares Shorted | 135.16 M | ||||
| Price To Sales | 78.03 X | ||||
| Revenue | 14.74 M | ||||
| Gross Profit | 82.18 M | ||||
| EBITDA | (264.43 M) | ||||
| Net Income | (413.64 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 504.17 M | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (391.24 M) | ||||
| Short Ratio | 2.79 X | ||||
| Earnings Per Share | (0.41) X | ||||
| Price To Earnings To Growth | 3.69 X | ||||
| Target Price | 11.8 | ||||
| Number Of Employees | 673 | ||||
| Beta | 0.017 | ||||
| Market Capitalization | 6.44 B | ||||
| Total Asset | 382.93 M | ||||
| Retained Earnings | (3.38 B) | ||||
| Working Capital | 129.64 M | ||||
| Net Asset | 382.93 M |
About Immunitybio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.